Zogenix Is Actively Developing Therapies For Rare Diseases To Address The Unmet Medical Needs Of Patients With Limited Or No Treatment Options.

The Pipeline

Our pipeline drives deeper scientific understanding for patients with rare epilepsies as we strive to improve outcomes.

ZX008 – Dravet syndrome

Lead investigational candidate, ZX008 (low-dose fenfluramine) for the treatment of Dravet syndrome, a rare form of pediatric- epilepsy with life threatening consequences

Formulation

Fenfluramine hydrochloride oral solution

Status

Phase 3 trials completed

  • Pivotal Phase 3 studies completed
  • Orphan drug designation in the United States and the European Union
  • Fast Track and Breakthrough Therapy

ZX008 – Lennox-Gastaut syndrome

Investigational product candidate, ZX008 (low-dose fenfluramine) for the treatment of Lennox-Gastaut syndrome (LGS), a debilitating and rare form of epilepsy

Formulation

Fenfluramine hydrochloride oral solution

Status

Global phase 3 trial ongoing